STOCK TITAN

SS Innovations Appoints Sarah M. Romano as Chief Financial Officer

(Neutral)
(Very Positive)
Tags

SS Innovations (Nasdaq: SSII) has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. She will be based in the United States and is expected to support the company’s next phase of global growth.

According to SS Innovations, Romano brings over 20 years of financial leadership in medical technology and life sciences, including CFO roles at Vicarious Surgical, Entero Therapeutics and Kiora Pharmaceuticals, where she led capital strategy, strategic transactions and SEC reporting, and helped raise more than $100 million through public and private financings.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

  • New CFO appointed effective August 3, 2026
  • Over two decades of medtech and life sciences finance experience
  • More than $100 million raised across public and private financings

Negative

  • None.

Market Context

Placed against an active S-3 shelf for up to $150,000,000 of securities and a separate ATM capacity,...
Analysis

Placed against an active S-3 shelf for up to $150,000,000 of securities and a separate ATM capacity, this CFO appointment occurs while SS Innovations trades well below its 52-week high and carries low reported short positioning, leaving dilution timing and capital deployment as key watch points.

Key Figures

CFO start date: August 3, 2026 Industry experience: more than two decades Capital raised: more than $100 million
3 metrics
CFO start date August 3, 2026 Effective date of Chief Financial Officer appointment
Industry experience more than two decades Medtech and life sciences finance leadership
Capital raised more than $100 million Public and private financings led by incoming CFO

Historical Context

5 past events · Latest: Jul 07 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jul 07 Training milestone Positive -4.0% Subsidiary SSICRS graduated first cardiac robotic surgery training class.
Jun 30 Industry award Positive +17.6% Named Outstanding Company winner at 2026 Surgical Robotics Industry Awards.
Jun 04 Technical milestone Positive -10.9% Reported completion of world’s longest-distance robotic telesurgery using SSi Mantra.
May 13 Earnings report Positive -2.9% Record Q1 2026 revenue with higher gross margin and narrower net loss.
May 07 Conference demo Positive -3.4% Demonstrated long-distance cross-border telesurgery at surgical congress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across the last five largely positive operational and financial updates, SS Innovations has more often traded down than up in the following session.

Key Terms

sec reporting, certified public accountant (cpa)
2 terms
sec reporting regulatory
"she led capital raising activities, strategic transactions, SEC reporting, and investor relations programs."
SEC reporting is the process by which publicly traded companies regularly share important financial information with the government agency responsible for overseeing the stock market. This information helps investors understand a company's financial health and make informed decisions, much like how a doctor’s check-up provides insight into a person's well-being. Consistent and transparent reporting ensures trust and fairness in the financial markets.
certified public accountant (cpa) financial
"and is a licensed Certified Public Accountant (CPA) in Massachusetts."
A certified public accountant (CPA) is a licensed accounting professional who prepares, examines and certifies financial statements, handles taxes, and conducts independent audits to verify a company’s reported numbers. For investors, a CPA’s stamp of approval is like a mechanic’s inspection for a car: it increases confidence that the financial information is accurate, reduces the chance of hidden problems, and helps assess the true financial health and risks of an investment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth

FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. Ms. Romano will be based in the United States.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We are thrilled to welcome Sarah as our Chief Financial Officer at this critical moment in our growth journey. As we continue our global expansion, including pursuing U.S. FDA approval of our advanced, cost-effective SSi Mantra surgical robotic system, Sarah brings strong financial leadership, keen strategic vision, and extensive capital markets experience. She will play an integral role in scaling and enhancing our financial operations to accommodate our anticipated growth.”

Ms. Romano added, “I am delighted for this opportunity to collaborate closely with Dr. Sudhir and the leadership team as SS Innovations delivers on its mission to democratize global access to cutting-edge surgical robotic care.”

Ms. Romano is a seasoned public company finance executive, bringing more than two decades of experience leading capital strategy, corporate growth, and financial operations in the medical technology and life sciences industries. Most recently, Ms. Romano served as Chief Financial Officer of Vicarious Surgical, a robotic surgery company where she led financial and operational initiatives to significantly reduce cash burn, strengthen the balance sheet, and support the company's strategic objectives. Previously, she served as Chief Financial Officer of Entero Therapeutics and Kiora Pharmaceuticals, where she led capital raising activities, strategic transactions, SEC reporting, and investor relations programs. Throughout her career, Ms. Romano has raised more than $100 million through public and private financings and has extensive experience supporting emerging growth public companies, including robotic surgery and medical technology organizations, through periods of transformation, growth, and strategic change.

Ms. Romano began her career as an auditor at PricewaterhouseCoopers and is a licensed Certified Public Accountant (CPA) in Massachusetts. She earned a Bachelor of Arts in Accounting from the College of the Holy Cross and Master of Accountancy in Accounting from Boston College.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient-related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group 
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.ai
512.354.7000 Office
Editor@IBN.Ai


FAQ

Who is the new CFO of SS Innovations (Nasdaq: SSII) in 2026?

SS Innovations appointed Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. According to SS Innovations, she is a veteran medtech finance executive with over two decades of experience in capital strategy, corporate growth and financial operations at medical technology and life sciences companies.

When does Sarah M. Romano start as CFO of SS Innovations (SSII)?

Sarah M. Romano’s appointment as Chief Financial Officer of SS Innovations is effective on August 3, 2026. According to SS Innovations, she will be based in the United States and will help scale and enhance financial operations to support the company’s anticipated global growth.

What experience does Sarah M. Romano bring to SS Innovations (SSII)?

Sarah M. Romano brings more than 20 years of finance experience in medical technology and life sciences. According to SS Innovations, she previously served as CFO of Vicarious Surgical, Entero Therapeutics and Kiora Pharmaceuticals, leading capital strategy, strategic transactions, SEC reporting and investor relations programs.

How has new SS Innovations (SSII) CFO Sarah M. Romano raised capital in her career?

According to SS Innovations, Sarah M. Romano has raised more than $100 million through public and private financings. She has extensive experience supporting emerging growth public companies, including robotic surgery and medical technology organizations, through periods of transformation, growth and strategic change.

How could the SS Innovations (SSII) CFO appointment support its global growth plans?

According to SS Innovations, Sarah M. Romano will play an integral role in scaling and enhancing financial operations. The company links her capital markets and strategic finance experience to supporting its global expansion and pursuit of U.S. FDA approval for the SSi Mantra surgical robotic system.